AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04432337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The role of the activation of the NLRP3 inflammasome after cardiac surgery
Description: Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
Study NCT05559879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabo + Dostarlimab
Description: Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
Study NCT05946265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: 120 patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) The dosimetric parameters for the treatment included a wavelength of 660 nm applied in continuous mode with a radiant power of 100 mW (0.1 W). The irradiance ranged from 35.385 mW/cm² to 35 W/cm², with a beam area of 0.002826 cm². Each point received an exposure time of 30 seconds, resulting in a radiant exposure of 1.061 J/cm² and a total radiant energy of 3 J. The procedure involved six irradiated points per tooth, distributed across the vestibular surface (apical, middle, and cervical regions) and the palatal surface. The application technique was performed in contact, maintaining a 90-degree angle to the surface. The treatment consisted of a single session.
Study NCT06630234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3009
Description: Administered orally
Study NCT04712097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
Study NCT04712097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
Study NCT04303208 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
Study NCT04712097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
Study NCT04712097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociluzumab
Description: Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
Study NCT06351345 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 129Xe Hyperpolarized
Description: Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
Study NCT06545916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunobinop
Description: 1 tablet taken orally at bedtime
Study NCT06545916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sunobinop
Description: 1 tablet taken orally at bedtime
Study NCT05164276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head position
Description: Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
Study NCT04899310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3705
Description: A sterile liquid for injection
Study NCT06529770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP-e
Description: The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience.
Study NCT06034028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Valve TF System
Description: The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
Study NCT05856552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy delivered by community resource persons via home visits.
Study NCT05856552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Activities
Description: Weekly hour-long group activities delivered by community resource persons in community spaces.
Study NCT06213311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given by IV
Study NCT06213311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given by IV
Study NCT06213311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axi-cel
Description: Given by IV
Study NCT05795842 — intervention group
Intervention type: DEVICE
Intervention: wearable wristband model
Description: MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
Study NCT05795842 — intervention group
Intervention type: OTHER
Intervention: Samsung Galaxy Watch 6
Description: The Samsung Galaxy Watch6 will collect study data on physiological signals with a compatible Samsung Galaxy phone S21. The Samsung Galaxy Watch6 will include various models, the difference being the size of the watch face or the analog front end of the device.~The software device is installed on the Samsung Galaxy Watch. The app on the watch continuously records PPG and/or ECG data and transmits it. The phone app allows study staff to enter the subject ID, initiate data collection, and stop data collection sessions on the watch. It also receives and stores PPG and ECG data from the paired watch. The PPG app used in the study does not trigger irregular rhythm notifications or display rhythm classification. The data collected using the PPG app will support algorithm development.
Study NCT05795842 — intervention group
Intervention type: DEVICE
Intervention: Standard of care extended ECG monitoring
Description: Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
Study NCT05832580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etidronate
Description: Etidronate in capsules of 200 mg or 400 mg.
Study NCT05832580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in similar capsules
Study NCT06350084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother's Touch
Description: Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
Study NCT06350084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse's Therapeutic Touch
Description: Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
Study NCT06646627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3CART
Description: Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg
Study NCT05652699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen
Description: Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
Study NCT05652699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
Study NCT05240976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE plus AIFA
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
Study NCT05240976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NMDAE plus Placebo Cap
Description: Use of an NMDA enhancer plus placebo as a comparator
Study NCT05725187 — intervention group
Intervention type: DEVICE
Intervention: MobiCare
Description: It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
Study NCT06348719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Description: The experimental procedure corresponds to robot-assisted laparoscopy.
Study NCT06348719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopy
Description: The control procedure corresponds to conventional laparoscopy.
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prospective cohort study
Description: A prospective cohort of patients will be set up to support the randomized controlled trial. Patients will be offered participation in this cohort if the center is unable to participate in the randomized trial (i.e., does not have a robot, or does not have a laparoscopic column with fluorescence), if the patient refuses randomization in the randomized controlled trial, if the surgeon refuses to randomize the patient, or if the surgeon does not meet the learning curve criteria required for robotic surgery. These patients will be followed in exactly the same way as patients included in the randomized controlled trial, once their consent has been obtained.
Study NCT04666155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Colonic Exoperistalsis with MOWOOT device
Description: Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both.
Study NCT04666155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of care with Trans-Anal Irrigation
Description: Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
Study NCT04666155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care with Trans-Anal Irrigation
Description: Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
Study NCT05946265 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: simulation of Photobiomodulation
Description: Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
Study NCT05895344 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton-therapy
Description: Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
Study NCT05895344 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon radiotherapy
Description: Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
Study NCT05198609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FOLFOX-HAIC
Description: Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
Study NCT05198609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
Study NCT05198609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
Study NCT05198609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib was administered orally 250mg once per day
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective cohort study
Description: Retrospective data collection from the medical records of all patients who underwent hysterectomy for low- or intermediate-risk endometrial cancer during the inclusion period at a participating center and who were not included in the randomized controlled trial or prospective cohort; up to a limit of 1000 inclusions. For this retrospective cohort, only data concerning initial age, BMI, histological type of cancer and surgical approach used will be collected.
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: information and consent
Description: information and consent
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information and consent
Description: information and consent
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information and consent
Description: information and consent
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomization
Description: Randomization
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: randomization
Description: Randomization
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Description: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Description: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Study NCT05198609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was administered orally 250mg once per day
Study NCT04972630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pal-Care
Description: Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies.
Study NCT05558254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robert - intervention to enhance muscle strength
Description: Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting.
Study NCT04972630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-Usual Care
Description: The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency.
Study NCT04973228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Foam
Description: Roflumilast 0.3% foam for topical application
Study NCT04973228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam for topical application
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Description: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgical data collection
Description: Surgical data collection at Day 0
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical data collection
Description: Surgical data collection at Day 0
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical data collection
Description: Surgical data collection at Day 0
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological data collection
Description: Biological data collection at Day 1
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological data collection
Description: Biological data collection at Day 1
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biological data collection
Description: Biological data collection at Day 1
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of histological data from the surgical specimen
Description: Collection of histological data from the surgical specimen et Day 42
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of histological data from the surgical specimen
Description: Collection of histological data from the surgical specimen et Day 42
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of histological data from the surgical specimen
Description: Collection of histological data from the surgical specimen et Day 42
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phone calls
Description: Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone calls
Description: Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3